When the world is counting on you, count on Signant
Vaccine Development
Reliable safety & efficacy data, and efficient study management
Whether you’re developing new vaccines for COVID-19, influenza, HSV, RSV, CMV, chickengunya, Lyme’s disease, or hantavirus, count on Signant to help you generate high-quality evidence for submission and labelling.
We know vaccine studies are often large and globally dispersed with sensitive timeframes, extended participant follow-up periods, multiphase designs, and critical data management needs. Leverage our Signant SmartSignals suite to navigate these challenges and gather the audit-ready, high quality evidence you need to get your vaccine to the public.
Our vaccine experience
0
STUDIES
0
COUNTRIES
0
PATIENTS
0
SCALES
Solutions to address clinical and operational challenges
- Efficient safety data capture
- Accurate disease surveillance
- Global supplies management
- Simplifying the patient journey
-
Efficient safety data capture
Efficient safety data capture
With thousands of participants reporting symptoms for 7-14 days after each vaccine intervention, trust Signant SmartSignals eCOA to drive high completion compliance and reliable data. Use our proprietary reactogenicity diary, or provide your own, to capture accurate, time-stamped data. Receive real-time alerts of high-grade adverse events for timely patient follow up and oversight, and eliminate the costly transcription errors and delays inherent with paper diaries.
-
Accurate disease surveillance
Accurate disease surveillance
Track the incidence of disease-like symptoms over extended surveillance periods to generate accurate evidence of vaccine efficacy. With SmartSignals eCOA implement tested approaches to long-term surveillance, driving continued participant engagement and data collection with minimal burden. Automated alerting ensures timely in-clinic follow-up for accurate incidence data generation.
-
Global supplies management
Global supplies management
Vaccine trials require accurate drug supply forecasting and a dynamic supply chain to support sites in regions where virus prevalence changes quickly. That's why top pharma companies save 10%+ annually from their drug supply budget by transforming forecasting and supply chain efficiency with Signant.
-
Simplifying the patient journey
Simplifying the patient journey
Leverage SmartSignals eConsent to enable rapid participant enrolment, and efficient reconsent when needed. Enable east access to study information from home or on site. Keep participants engaged during long follow-up periods using in-app patient engagement features and telemedicine for remote video-based follow-up consultations.
When Pfizer needed eCOA
ASAP for their COVID vaccine program,
we answered the call
0
SITES
0
PATIENTS
0
COUNTRIES
0
WEEK IMPLEMENTATION
Watch and read more about our vaccine study expertise
COVID-19 | Real-Time Data
Covid-19 | Count on Signant
Learn how our eClinical technology enhances vaccine study evidence for submissions and labeling
Allow our experts to assist in reviewing your upcoming vaccine protocol and advising you on the optimal integration of eClinical technology